Managing the chronic welfare impact of canine atopic dermatitis and the evidence base for modern treatment options.
Canine atopic dermatitis is one of the most welfare-significant common conditions in companion animals because of its chronicity, its intensity and the compounding distress of the itch-scratch cycle. A dog that scratches constantly cannot sleep normally, cannot engage comfortably with its environment and may develop open wounds, skin thickening and permanent coat changes. The psychological impact — reduced playfulness, social withdrawal, irritability — is consistent with chronic pain-driven behavioural change. Modern targeted biologics have transformed the welfare outlook for atopic dogs: lokivetmab provides fast, targeted itch control with a safety profile far better than long-term steroids, enabling affected dogs to achieve near-normal quality of life.